Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Gynecologic Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.24.18_SUPPL.15055PMID 16375950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

  2004cited by this paper
• Activity of docetaxel in paclitaxel-resistant ovarian cancer cells

  2004cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

  2003cited by this paper
• Docetaxel in combination with carboplatin for chemo‐naive patients with epithelial ovarian cancer

  2002cited by this paper
• Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

  2001cited by this paper
• What Is the “Best” Platinum: Cisplatin, Carboplatin, or Oxaliplatin?

  2001cited by this paper
• A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.

  2000cited by this paper
• Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cited by this paper
• Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

  1999cited by this paper
• Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.

  1998cited by this paper
• Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

  1997cited by this paper
• Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.

  1996cited by this paper
• Peripheral neuropathy secondary to docetaxel (Taxotere)

  1996cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.

  1995cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper

• Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

  2020cites this paper
• Safe administration of docetaxel after weekly paclitaxel-induced acute pancreatitis

  2017cites this paper
• Favourable prognosis with modified dosing of docetaxel and cisplatin in Japanese patients with ovarian cancer.

  2009cites this paper
• [Standards, Options: Recommendations for the management of patients with epithelial ovarian cancer. Medical front-line treatment (summary report, update 2008)].

  2008cites this paper